Twist Bioscience (TWST) 10-Q 10 Feb 20 2020 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Dec. 31, 2019	Feb. 06, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Registrant Name	Twist Bioscience Corp
Entity Central Index Key	0001581280
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Security Exchange Name	NASDAQ
Entity Address, State or Province	CA
Title of 12(b) Security	Common Stock
Trading Symbol	TWST
Entity Common Stock, Shares Outstanding		35,446,291
Entity Incorporation, State or Country Code	DE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Current assets
Cash and cash equivalents	$ 26,032	$ 46,735
Short-term investments	77,075	91,372
Accounts receivable, net	13,054	12,104
Inventories	7,416	7,330
Prepaid expenses and other current assets	5,711	2,594
Total current assets	129,288	160,135
Property and equipment, net	21,339	20,835
Operating lease right-of-use assets	37,238
Goodwill	1,138	1,138
Intangible assets, net	458	508
Restricted cash, non-current	579	579
Other non-current assets	2,237	3,799
Total assets	192,277	186,994
Current liabilities
Accounts payable	9,106	9,760
Accrued expenses	4,687	5,965
Accrued compensation	8,848	10,479
Accrued litigation settlement	22,500
Current portion of operating lease liabilities	8,371
Current portion of long-term debt	3,333	3,333
Other current liabilities	999	817
Total current liabilities	57,844	30,354
Operating lease liabilities, net of current portion	27,539
Long-term debt, net of current portion	3,669	4,400
Other non-current liabilities	144	158
Total liabilities	89,196	34,912
Commitments and contingencies (Note 6)
Stockholders' equity
Preferred stock, $0.00001 par value—10,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.00001 par value—100,000,000 shares authorized; 33,260,761 and 32,872,675 shares issued and outstanding as of as of December 31, 2019 and September 30, 2019, respectively.
Additional paid-in capital	477,053	470,425
Accumulated other comprehensive income	190	181
Accumulated deficit	(374,162)	(318,524)
Total stockholders' equity	103,081	152,082
Total liabilities and stockholders' equity	$ 192,277	$ 186,994

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Sep. 30, 2019
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, share authorized	10,000,000	10,000,000
Preferred stock, share issued	0	0
Preferred stock, share outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, share authorized	100,000,000	100,000,000
Common stock, share issued	33,260,761	32,872,675
Common stock, share outstanding	33,260,761	32,872,675

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statement of Comprehensive Income [Abstract]
Revenues	$ 17,164	$ 11,492
Operating expenses:
Cost of revenues	13,792	11,857
Research and development	10,297	7,273
Selling, general and administrative	26,405	15,259
Litigation settlement	22,500
Total operating expenses	72,994	34,389
Loss from operations	(55,830)	(22,897)
Interest income	564	664
Interest expense	(248)	(348)
Other income (expense), net	(87)	(15)
Loss before income taxes	(55,601)	(22,596)
Provision for income taxes	(37)	(43)
Net loss attributable to common stockholders	(55,638)	(22,639)
Other comprehensive loss:
Change in unrealized loss on investments	16	(7)
Foreign currency translation adjustment	(7)	(56)
Comprehensive loss	$ (55,629)	$ (22,702)
Net loss per share attributable to common stockholders—basic and diluted	$ (1.69)	$ (1.18)
Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted	32,976,145	19,187,533

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Series A Redeemable Convertible Preferred Stock [Member]	Series B Redeemable Convertible Preferred Stock [Member]	Series C Redeemable Convertible Preferred Stock [Member]	Series D Redeemable Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Accumulated deficit [Member]
Beginning Balance at Sep. 30, 2018		$ 9,141	$ 25,900	$ 36,726	$ 218,716
Beginning Balance , shares at Sep. 30, 2018		2,817,723	3,315,645	2,491,483	10,326,454
Conversion of redeemable convertible preferred stock to common stock		$ (9,141)	$ (25,900)	$ (36,726)	$ (218,716)
Conversion of redeemable convertible preferred stock to common stock, shares		(2,817,723)	(3,315,645)	(2,491,483)	(10,326,454)
Ending Balance at Dec. 31, 2018	$ 0	$ 0	$ 0		$ 0
Ending Balance , shares at Dec. 31, 2018		0	0	0	0
Beginning Balance at Sep. 30, 2018	(201,422)						$ 9,346	$ 87	$ (210,855)
Beginning Balance , shares at Sep. 30, 2018						3,206,048
Issuance of common stock in public offering	69,597						69,597
Issuance of common stock in public offering, shares						5,750,000
Exercise of stock options	166						166
Exercise of stock options , shares						48,841
Conversion of redeemable convertible preferred stock warrant liability to equity	631						631
Conversion of redeemable convertible preferred stock to common stock	290,462						290,462
Conversion of redeemable convertible preferred stock to common stock , shares						18,951,305
Repurchases of early exercised stock options, shares						(442)
Stock-based compensation	1,864						1,864
Net exercise of stock warrants , shares						57,122
Other comprehensive income	(63)							(63)
Net loss	(22,639)								(22,639)
Ending Balance at Dec. 31, 2018	138,596						372,066	24	(233,494)
Ending Balance , shares at Dec. 31, 2018						28,012,874
Beginning Balance at Sep. 30, 2019	152,082						470,425	181	(318,524)
Beginning Balance , shares at Sep. 30, 2019						32,872,675
Issuance of common stock in public offering	2,024						$ 2,024
Issuance of common stock in public offering, shares						96,827
Vesting of restricted stock units, shares							84,565
Exercise of stock options	1,715						$ 1,715
Exercise of stock options , shares						242,382
Repurchases of early exercised stock options, shares						(896)
Repurchases of common stock for income tax withholding , shares						(34,792)
Repurchases of common stock for income tax withholding	(808)						(808)
Stock-based compensation	3,697						3,697
Other comprehensive income	9							9
Net loss	(55,638)								(55,638)
Ending Balance at Dec. 31, 2019	$ 103,081						$ 477,053	$ 190	$ (374,162)
Ending Balance , shares at Dec. 31, 2019						33,260,761

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Common Stock [Member]
Net of underwriting discounts, commissions and offering expenses	$ 276	$ 10,903

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net loss	$ (55,638)	$ (22,639)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	1,505	1,472
Loss on disposal of property and equipment		8
Non-cash lease expense	236
Stock-based compensation	3,697	1,864
Discount accretion on investment securities	(150)
Non-cash interest expense	46	64
Amortization of debt discount	56	78
Changes in assets and liabilities:
Accounts receivable, net	(950)	(1,559)
Inventories	(86)	467
Prepaid expenses and other current assets	(2,917)	(366)
Other non-current assets	62	(392)
Accounts payable	(556)	(715)
Accrued expenses	(1,279)	39
Accrued compensation	(1,629)	(140)
Accrued litigation settlement	22,500
Other liabilities	189	135
Net cash used in operating activities	(34,914)	(21,684)
Cash flows from investing activities
Purchases of property and equipment	(2,058)	(1,922)
Purchases of investments	(6,537)	(63,835)
Proceeds from maturity of investments	21,000
Net cash provided by (used in) investing activities	12,405	(65,757)
Cash flows from financing activities
Proceeds from exercise of stock options	1,674	220
Proceeds from public offering, net of underwriting discounts and commissions and offering expenses	2,024	72,779
Repayments of long-term debt	(833)
Repurchases of common stock for income tax withholding	(808)
Net cash provided by financing activities	2,057	72,999
Effect of exchange rates on cash, cash equivalents and restricted cash	9
Net increase (decrease) in cash, cash equivalents and restricted cash	(20,443)	(14,442)
Cash, cash equivalents, and restricted cash at beginning of year	47,398	81,537
Cash, cash equivalents, and restricted cash at end of year	26,955	67,095
Supplemental disclosure of cash flow information
Interest paid	146	207
Income taxes paid, net of refunds	44	53
Non-cash investing and financing activities
Property and equipment additions included in accrued expenses and accounts payable	66	1,117
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	$ 2,833
Deferred offering costs included in accounts payable and accrued expenses		826
Conversion of redeemable convertible preferred stock warrant liability to equity		631
Conversion of redeemable convertible preferred stock to common stock		$ 290,462

The company

The company	3 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. The Company Twist Bioscience Corporation (the Company) was incorporated in the state of Delaware on February 4, 2013. The Company is a synthetic biology and genomics The Company has generated net losses in all periods since its inception. As of December 31, 2019, the Company had an accumulated deficit of $374.2 million and has not generated positive cash flows from operations since inception. Losses are expected to continue as the Company continues to invest in product development, manufacturing, and sales and marketing. The Company has raised multiple rounds of debt and equity financing since its inception. In October 2018, the Company completed an initial public offering (IPO) of its common stock which raised proceeds of $69.6 million, after deducting underwriting discounts and In December 2019, the Company commenced an at-the-market offering of its common stock with proceeds of $2.0 million, after deducting underwriting discounts and commissions and offering expenses, in the three months ended December 31, 2019. it If the Company requires but is unable to obtain additional funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.

Summary of significant accounti

Summary of significant accounting policies	3 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of significant accounting policies	2. Summary of significant accounting policies Basis of presentation and use of estimates The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K Form 10-K) 2 The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly-owned subsidiaries. All intercompany balances and accounts are eliminated in consolidation. Significant accounting policies There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K in " Recently adopted accounting pronouncements – Leases Recent accounting pronouncements Recently adopted accounting pronouncements – Leases In February 2016, the Financial Accounting Standards Board ( ) Accounting Standard Update ( ASU ) Leases 2018-10, Codification Improvements to Topic 842, Leases 2018-11, Leases (Topic 842): Targeted Improvements right-of-use On October 1, 2019, the Company adopted Topic 842 using the modified retrospective approach. The adoption had a material effect on the condensed consolidated balance sheets, but did not have a material effect on the condensed consolidated statements of operations and comprehensive loss. Prior period amounts were not adjusted and continue to be reported in accordance with the previous accounting under ASC 840, Leases As a result of electing the transition guidance as described above, on October 1, 2019, the Company recorded operating lease right-of-use Under Topic 842, the Company determines if an arrangement is a lease at inception primarily based on the determination of the party responsible for directing the use of an underlying asset within a contract. Operating lease right-of-use right-of-use committed , annual percentage yields from corporate debt financings of companies of similar size and credit rating over a loan term approximating the remaining term of each lease, and government bond yields for terms approximating the remaining term of each lease in countries where the leased assets are located. Certain leases include payments of operating expenses that are dependent and may be revised based on the landlord’s estimate, and these variable payments are therefore excluded from the lease payments used to determine the operating lease right-of-use asset and lease liability The Company elected to not apply the recognition requirements of Topic 842 to short-term leases with terms of 12 months or less which do not include an option to purchase the underlying asset that the Company is T non-lease Additional information and disclosures required by Topic 842 are contained in Note 6. Recently issued accounting pronouncements not yet adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments held-to-maturity available-for-sale In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Subtopic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement ASU 2018-13 In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes Income Taxes

Fair value measurement

Fair value measurement	3 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair value measurement	3. Fair value measurement The Company assesses the fair value of financial instruments based on the provisions of ASC 820, Fair Value Measurements Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company short-term investments primarily utilize broker quotes in a non-active Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2019 and September 30, 2019 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. December 31, 2019 (in thousands) Level 1 Level 2 Level 3 Fair value Assets Cash $ 16,444 $ — $ — $ 16,444 Money market funds 9,588 — — 9,588 Corporate bonds — 8,523 — 8,523 Commercial paper — 21,515 — 21,515 U.S. government treasury bills 47,037 — — 47,037 Totals $ 73,069 $ 30,038 $ — $ 103,107 September 30, 2019 (in thousands) Level 1 Level 2 Level 3 Fair value Assets Cash $ 19,344 $ — $ — $ 19,344 Money market funds 27,390 — — 27,390 Corporate bonds — 8,530 — 8,530 Commercial paper — 28,361 — 28,361 U.S. government treasury bills 54,482 — — 54,482 Totals $ 101,216 $ 36,891 $ — $ 138,107 As of December 31, 2019 and September 30, 2019, gross unrealized gains and unrealized losses for cash equivalents and short-term investments were not material, and the contractual maturities of all marketable securities were less than one year.

Balance sheet components

Balance sheet components	3 Months Ended
	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Balance sheet components	4. Balance sheet components The Company’s accounts receivable, net balance consists of the following: (in thousands) December 31, September 30, Trade Receivables $ 12,475 $ 11,085 Other Receivables 920 1,313 Allowance for Doubtful Accounts (341 ) (294 ) Accounts Receivable, net $ 13,054 $ 12,104 Inventory amounts consist of the following: (in thousands) December 31, 2019 September 30, 2019 Raw Materials $ 5,248 $ 4,900 Work-in-process 1,300 1,157 Finished Goods 868 1,273 $ 7,416 $ 7,330

Goodwill and intangible assets

Goodwill and intangible assets	3 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and intangible assets	5. Goodwill and intangible assets There were no changes to the carrying value of goodwill as of December 31, 2019 and September 30, 2019. Total amortization expense related to intangible assets was less than $0.1 million for the three months ended December 3 1 The intangible assets balances are presented below: December 31, 2019 (in thousands, except for years) Useful life in years Gross carrying amount Accumulated amortization Net book value Developed Technology 6 $ 1,220 $ (762 ) $ 458 Tradenames & Trademarks 2 20 (20 ) — Total indefinite-lived intangible assets $ 1,240 $ (782 ) $ 458 September 30, 2019 (in thousands, except for years) Useful life in years Gross carrying amount Accumulated amortization Net book value Developed Technology 6 $ 1,220 $ (712 ) $ 508 Tradenames & Trademarks 2 20 (20 ) — Total indefinite-lived intangible assets $ 1,240 $ (732 ) $ 508

Commitments and contingencies

Commitments and contingencies	3 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	6. Commitments and contingencies Litigation On February 3, 2016, Agilent filed a lawsuit against the Company it s (the Complaint ), C On December 7, 2018, the Court granted Agilent’s motion to amend its complaint, permitting Agilent to file its Second Amended Complaint. This new complaint added amended allegations against the Company and Dr. Leproust, and also new claims for breach of contract and trade secret misappropriation against two individuals: Dr. Siyuan Chen, a current Company employee and Solange Glaize, a former Company employee. The Court also set trial to begin on February 24, 2020. On February 6, 2020, the Company , Dr. Leproust, Dr. Chen, Ms. Glaize (together, the Twist Group) and Agilent agreed to the terms of a settlement agreement (the Settlement Agreement) pursuant to which the Twist Group and Agilent each agreed to request dismissal of all claims against each other. The Settlement Agreement resolves the litigation initially commenced by the Complaint and contains no admission of liability or wrongdoing. Pursuant to the Settlement Agreement, the Company agreed to pay Agilent $22.5 million in ca sh the Settlement Agreement. This amount has been accrued in the consolidated financial statements in the three months ended December 31, 2019. In addition, the Twist Group and Agilent each agreed to release the other party from all known and unknown claims related to the claims and counterclaims alleged or that could have been alleged in such litigation or that arise from the facts and events that gave rise to such litigation. Further, Agilent agreed to grant the Company a limited non-exclusive license to use the trade secrets asserted by Agilent in the litigation, which extends to the Company’s supply chain, including its customers, suppliers, distributors and resellers. Agilent also agreed not to sue the Company for the infringement of any Agilent patent issued or pending as of the date of the Settlement Agreement or claim priority thereto, solely to the extent such patents claim a trade secret alleged in the litigation. There is no other covenant or release of claims for patent infringement. Dismissal of the case with the court is expected in February 2020. Indemnifications In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend the indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. To date, the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require it to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by corporate law. The Company also has directors’ and officers’ insurance. Leases The Company leases certain of its facilities under non-cancellable operating Future minimum lease payments under all non-cancelable operating (in thousands) Operating leases Years ending September 30: Remainder of 2020 $ 6,757 2021 6,687 2022 6,762 2023 6,429 2024 6,388 Thereafter 11,291 Total minimum lease payments $ 44,314 Less: imputed interest (8,404 ) Total operating lease liabilities $ 35,910 Less: current portion (8,371 ) Operating lease obligations, net of current portion $ 27,539 Operating lease expense was $2.0 million for the three months ended December 31, 2019. Cash payments for amounts included in the measurement of operating lease liabilities were $1.9 million for the three months ended December 31, 2019.

Related party transactions

Related party transactions	3 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related party transactions	7. Related party transactions During the three months ended December 31, 2019 and 2018, the Company purchased raw materials from a related party investor in the amount of $0.7 million and $1.2 million, respectively. Payable balances and cash receipts and receivable balances with the related parties were immaterial as of December 31, 2019 and September 30, 2019.

Income taxes

Income taxes	3 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income taxes	8. Income taxes In determining quarterly provisions for income taxes, the Company uses the annual estimated effective tax rate applied to the actual year-to-date

Warrants

Warrants	3 Months Ended
	Dec. 31, 2019
Text Block [Abstract]
Warrants	9. Warrants Outstanding warrants for the Company’s common stock, issued in connection with its long-term debt agreements, were as follows: (in thousands, except share and per share data) Number of shares underlying warrants Exercise December 31, 2019 Issuance date Expiration date price per share Warrant class/series: Common stock warrants 18,854 December 22, 2015 December 22, 2025 $ 14.85 Common stock warrants 7,531 March 28, 2016 March 28, 2026 $ 21.24 Total common stock warrants 26,385 (in thousands, except share and per share data) Number of shares underlying warrants Exercise September 30, 2019 Issuance date Expiration date price per share Warrant class/series: Common stock warrants 18,854 December 22, 2015 December 22, 2025 $ 14.85 Common stock warrants 7,531 March 28, 2016 March 28, 2026 $ 21.24 Total common stock warrants 26,385

Common stock

Common stock	3 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Common stock	10. Common stock At-the-Market Offering (the “ATM”) In December 2019, the Company the its the C its and

Stock-based compensation

Stock-based compensation	3 Months Ended
	Dec. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation	11. Stock-based compensation 2018 Equity Incentive Plan On September 26, 2018, the board of directors adopted the 2018 Equity Incentive Plan (the 2018 Plan) as a successor to the 2013 Stock Plan (the 2013 Plan). The number of shares reserved for issuance under the 2018 Plan upon approval of the plan was 5,856,505 shares of the Company’s common stock, and it increases automatically on the first day of each fiscal year, following the fiscal year in which the 2018 Plan became effective, by a number equal to the least of 999,900 shares, 4% of the shares of common stock outstanding at that time, or such number of shares determined by the Company’s board of directors. As of February 10, 2020, all common shares issuable under the 2018 Plan have been registered pursuant to registration statements on Form S-8. Any shares subject to outstanding awards under the 2013 Equity Incentive Plan that are canceled or repurchased subsequent to the 2018 Plan’s effective date are returned to the pool of shares reserved for issuance under the 2018 Plan. Awards granted under the 2018 Plan may be nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, and performance units. Activity under the equity incentive plans during the three months ended December 31, 2019 is summarized below: Shares available Options outstanding Weighted average exercise price per share Weighted average remaining contractual term (years) Aggregate intrinsic value Outstanding at September 30, 2019 1,520,875 3,550,445 $ 15.99 8.25 $ 31,997,934 Additional shares authorized 999,900 — Stock options granted (935,273 ) 935,273 $ 24.08 Stock options exercised — (242,382 ) $ 6.95 Stock options forfeited 33,139 (33,139 ) $ 25.94 Restricted stock units granted (190,786 ) — — Forfeiture of restricted stock units 3,483 — — Shares withheld for payment of taxes 34,792 — — Early exercised options repurchased 896 — Outstanding at December 31, 2019 1,467,026 4,210,197 $ 18.23 8.51 $ 22,020,849 Vested or expected to vest at December 31, 2019 4,210,197 $ 18.23 8.51 $ 22,020,849 Vested and exercisable at December 31, 2019 1,349,270 $ 11.32 7.32 $ 14,339,780 Total stock-based compensation expense recognized was as follows: Three months ended December 31, (in thousands) 2019 2018 Cost of revenues $ 360 $ 251 Research and development 728 300 Selling, general and administrative 2,609 1,313 Total stock-based compensation $ 3,697 $ 1,864 As of December 31, 2019, there was $36.6 million of total unrecognized compensation cost related to non-vested Restricted Stock Units Restricted stock primarily consists of restricted stock unit awards (RSUs) which have been granted to employees. The value of an RSU award is based on the Company’s stock price on the date of grant. The shares underlying the RSU awards are not issued until the RSUs vest. Upon vesting, each RSU converts into one share of the Company’s common stock. Activity with respect to the Company’s restricted stock units during the three months ended December 31, 2019 was as follows: (in thousands, except share and per share data) Number of Shares Weighted average grant date per share Weighted average remaining contractual term (years) Aggregate Intrinsic Value Outstanding at September 30, 2019 462,370 $ 26.16 3.91 $ 8,959,223 Restricted stock units granted 190,786 $ 24.11 Restricted stock units vested (83,956 ) $ 26.36 Restricted stock units forfeited (3,483 ) $ 29.17 Outstanding at December 31, 2019 565,717 $ 25.42 3.77 $ 14,383,146 Expected to vest at December 31, 2019 565,717 $ 25.42 3.77 $ 14,383,146 As of December 31, 2019, there was $15.1 million of total unrecognized compensation cost related to these issuances that is expected to be recognized over a weighted average period of 3.78 years. 2018 Employee Stock Purchase Plan On September 26, 2018, the board of directors adopted the 2018 Employee Stock Purchase Plan (the 2018 ESPP). The number of shares reserved for issuance under the 2018 ESPP upon approval was 275,225 share s Shares available Outstanding at September 30, 2019 56,081 Additional shares authorized 249,470 Outstanding at December 31, 2019 305,551 Subject to any plan limitations, the 2018 ESPP allows eligible service providers (through qualified and non-qualified Form S-8. Unless otherwise determined by the board of directors, the Company’s common stock will be purchased for the accounts of employees participating in the 2018 ESPP at a price per share that is the lesser of 85% of the fair market value of the Company’s common stock on the first trading day of the offering period, or 85% of the fair market value of the Company’s common stock on the last trading day of the offering period. During the three months ended December 31, 2019 and 2018,

Net loss per share attributable

Net loss per share attributable to common stockholders	3 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Net loss per share attributable to common stockholders	12. Net loss per share attributable to common stockholders The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders: Three months ended (in thousands, except share and per share data) 2019 2018 Numerator: Net loss attributable to common stockholders $ (55,638 ) $ (22,639 ) Denominator: Weighted average shares used in computing net loss per share, basic and diluted 32,976,145 19,187,533 Net loss per share attributable to common stockholders, basic and diluted $ (1.69 ) $ (1.18 ) The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented are as follows: Three months ended (in thousands, except share and per share data) 2019 2018 Shares subject to options to purchase common stock 4,210,197 3,500,040 Unvested restricted shares of common stock 13,635 81,473 Unvested restricted stock units 565,717 395,698 Unvested shares of common stock issued upon early exercise of stock options 32,614 59,548 Shares subject to employee stock purchase plan 79,708 — Shares subject to warrants to purchase common stock 26,385 74,670 Total 4,928,256 4,111,429

Geographic, product and industr

Geographic, product and industry information	3 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Geographic, product and industry information	13. Geographic, product and industry information The table below sets forth revenues by geographic region, based on ship-to North America Three months ended December 31, (in thousands) 2019 2018 United States $ 9,827 $ 8,569 EMEA 5,941 2,435 APAC 1,241 420 North America 155 68 Total $ 17,164 $ 11,492 The table below sets forth revenues by products. Three months ended December 31, (in thousands) 2019 2018 Synthetic genes $ 7,836 $ 6,511 Oligo pools 1,242 810 DNA libraries 1,057 413 NGS tools 7,029 3,758 Total $ 17,164 $ 11,492 The table below sets forth revenues by industry. Three months ended December 31, (in thousands) 2019 2018 Industrial chemicals $ 6,137 $ 5,346 Academic research 4,951 1,972 Healthcare 5,835 3,981 Agricultural 241 193 Total $ 17,164 $ 11,492

Subsequent events

Subsequent events	3 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent events	14. Subsequent events In January 20 20 2,142,853 under the ATM 47.7 46.0 underwriting discounts and

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	3 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of presentation and use of estimates	Basis of presentation and use of estimates The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K Form 10-K) 2 The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly-owned subsidiaries. All intercompany balances and accounts are eliminated in consolidation.
Significant accounting policies	Significant accounting policies There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K in " Recently adopted accounting pronouncements – Leases
Recent accounting pronouncements	Recent accounting pronouncements Recently adopted accounting pronouncements – Leases In February 2016, the Financial Accounting Standards Board ( ) Accounting Standard Update ( ASU ) Leases 2018-10, Codification Improvements to Topic 842, Leases 2018-11, Leases (Topic 842): Targeted Improvements right-of-use On October 1, 2019, the Company adopted Topic 842 using the modified retrospective approach. The adoption had a material effect on the condensed consolidated balance sheets, but did not have a material effect on the condensed consolidated statements of operations and comprehensive loss. Prior period amounts were not adjusted and continue to be reported in accordance with the previous accounting under ASC 840, Leases As a result of electing the transition guidance as described above, on October 1, 2019, the Company recorded operating lease right-of-use Under Topic 842, the Company determines if an arrangement is a lease at inception primarily based on the determination of the party responsible for directing the use of an underlying asset within a contract. Operating lease right-of-use right-of-use committed , annual percentage yields from corporate debt financings of companies of similar size and credit rating over a loan term approximating the remaining term of each lease, and government bond yields for terms approximating the remaining term of each lease in countries where the leased assets are located. Certain leases include payments of operating expenses that are dependent and may be revised based on the landlord’s estimate, and these variable payments are therefore excluded from the lease payments used to determine the operating lease right-of-use asset and lease liability The Company elected to not apply the recognition requirements of Topic 842 to short-term leases with terms of 12 months or less which do not include an option to purchase the underlying asset that the Company is T non-lease Additional information and disclosures required by Topic 842 are contained in Note 6. Recently issued accounting pronouncements not yet adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments held-to-maturity available-for-sale In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Subtopic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement ASU 2018-13 In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes Income Taxes

Fair value measurement (Tables)

Fair value measurement (Tables)	3 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2019 and September 30, 2019 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. December 31, 2019 (in thousands) Level 1 Level 2 Level 3 Fair value Assets Cash $ 16,444 $ — $ — $ 16,444 Money market funds 9,588 — — 9,588 Corporate bonds — 8,523 — 8,523 Commercial paper — 21,515 — 21,515 U.S. government treasury bills 47,037 — — 47,037 Totals $ 73,069 $ 30,038 $ — $ 103,107 September 30, 2019 (in thousands) Level 1 Level 2 Level 3 Fair value Assets Cash $ 19,344 $ — $ — $ 19,344 Money market funds 27,390 — — 27,390 Corporate bonds — 8,530 — 8,530 Commercial paper — 28,361 — 28,361 U.S. government treasury bills 54,482 — — 54,482 Totals $ 101,216 $ 36,891 $ — $ 138,107

Balance sheet components (Table

Balance sheet components (Tables)	3 Months Ended
	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Schedule Of Accounts Notes Loans And Financing Receivable	The Company’s accounts receivable, net balance consists of the following: (in thousands) December 31, September 30, Trade Receivables $ 12,475 $ 11,085 Other Receivables 920 1,313 Allowance for Doubtful Accounts (341 ) (294 ) Accounts Receivable, net $ 13,054 $ 12,104
Summary of Inventory	Inventory amounts consist of the following: (in thousands) December 31, 2019 September 30, 2019 Raw Materials $ 5,248 $ 4,900 Work-in-process 1,300 1,157 Finished Goods 868 1,273 $ 7,416 $ 7,330

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	3 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets Balances	The intangible assets balances are presented below: December 31, 2019 (in thousands, except for years) Useful life in years Gross carrying amount Accumulated amortization Net book value Developed Technology 6 $ 1,220 $ (762 ) $ 458 Tradenames & Trademarks 2 20 (20 ) — Total indefinite-lived intangible assets $ 1,240 $ (782 ) $ 458 September 30, 2019 (in thousands, except for years) Useful life in years Gross carrying amount Accumulated amortization Net book value Developed Technology 6 $ 1,220 $ (712 ) $ 508 Tradenames & Trademarks 2 20 (20 ) — Total indefinite-lived intangible assets $ 1,240 $ (732 ) $ 508

Commitments and contingencies (

Commitments and contingencies (Tables)	3 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum lease payments under all non-cancelable operating (in thousands) Operating leases Years ending September 30: Remainder of 2020 $ 6,757 2021 6,687 2022 6,762 2023 6,429 2024 6,388 Thereafter 11,291 Total minimum lease payments $ 44,314 Less: imputed interest (8,404 ) Total operating lease liabilities $ 35,910 Less: current portion (8,371 ) Operating lease obligations, net of current portion $ 27,539

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Dec. 31, 2019
Text Block [Abstract]
Summary of Issued Warrants for Its Redeemable Convertible Preferred Stock and Common Stock	Outstanding warrants for the Company’s common stock, issued in connection with its long-term debt agreements, were as follows: (in thousands, except share and per share data) Number of shares underlying warrants Exercise December 31, 2019 Issuance date Expiration date price per share Warrant class/series: Common stock warrants 18,854 December 22, 2015 December 22, 2025 $ 14.85 Common stock warrants 7,531 March 28, 2016 March 28, 2026 $ 21.24 Total common stock warrants 26,385 (in thousands, except share and per share data) Number of shares underlying warrants Exercise September 30, 2019 Issuance date Expiration date price per share Warrant class/series: Common stock warrants 18,854 December 22, 2015 December 22, 2025 $ 14.85 Common stock warrants 7,531 March 28, 2016 March 28, 2026 $ 21.24 Total common stock warrants 26,385

Stock-based compensation (Table

Stock-based compensation (Tables)	3 Months Ended
	Dec. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Activity Under The Equity Incentive Plans	Activity under the equity incentive plans during the three months ended December 31, 2019 is summarized below: Shares available Options outstanding Weighted average exercise price per share Weighted average remaining contractual term (years) Aggregate intrinsic value Outstanding at September 30, 2019 1,520,875 3,550,445 $ 15.99 8.25 $ 31,997,934 Additional shares authorized 999,900 — Stock options granted (935,273 ) 935,273 $ 24.08 Stock options exercised — (242,382 ) $ 6.95 Stock options forfeited 33,139 (33,139 ) $ 25.94 Restricted stock units granted (190,786 ) — — Forfeiture of restricted stock units 3,483 — — Shares withheld for payment of taxes 34,792 — — Early exercised options repurchased 896 — Outstanding at December 31, 2019 1,467,026 4,210,197 $ 18.23 8.51 $ 22,020,849 Vested or expected to vest at December 31, 2019 4,210,197 $ 18.23 8.51 $ 22,020,849 Vested and exercisable at December 31, 2019 1,349,270 $ 11.32 7.32 $ 14,339,780
Total Stock-based Compensation Expense	Total stock-based compensation expense recognized was as follows: Three months ended December 31, (in thousands) 2019 2018 Cost of revenues $ 360 $ 251 Research and development 728 300 Selling, general and administrative 2,609 1,313 Total stock-based compensation $ 3,697 $ 1,864
Schedule of Nonvested Restricted Stock Units Activity	Activity with respect to the Company’s restricted stock units during the three months ended December 31, 2019 was as follows: (in thousands, except share and per share data) Number of Shares Weighted average grant date per share Weighted average remaining contractual term (years) Aggregate Intrinsic Value Outstanding at September 30, 2019 462,370 $ 26.16 3.91 $ 8,959,223 Restricted stock units granted 190,786 $ 24.11 Restricted stock units vested (83,956 ) $ 26.36 Restricted stock units forfeited (3,483 ) $ 29.17 Outstanding at December 31, 2019 565,717 $ 25.42 3.77 $ 14,383,146 Expected to vest at December 31, 2019 565,717 $ 25.42 3.77 $ 14,383,146
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity	The number of shares reserved for issuance as at December 31, 2019 is as follows: Shares available Outstanding at September 30, 2019 56,081 Additional shares authorized 249,470 Outstanding at December 31, 2019 305,551

Net loss per share attributab_2

Net loss per share attributable to common stockholders (Tables)	3 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Computation of the Company's Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders: Three months ended (in thousands, except share and per share data) 2019 2018 Numerator: Net loss attributable to common stockholders $ (55,638 ) $ (22,639 ) Denominator: Weighted average shares used in computing net loss per share, basic and diluted 32,976,145 19,187,533 Net loss per share attributable to common stockholders, basic and diluted $ (1.69 ) $ (1.18 )
Summary of Calculation of Diluted Net Loss Per Share	The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented are as follows: Three months ended (in thousands, except share and per share data) 2019 2018 Shares subject to options to purchase common stock 4,210,197 3,500,040 Unvested restricted shares of common stock 13,635 81,473 Unvested restricted stock units 565,717 395,698 Unvested shares of common stock issued upon early exercise of stock options 32,614 59,548 Shares subject to employee stock purchase plan 79,708 — Shares subject to warrants to purchase common stock 26,385 74,670 Total 4,928,256 4,111,429

Geographic, product and indus_2

Geographic, product and industry information (Tables)	3 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Summary of Revenue by Geographic Region	The table below sets forth revenues by geographic region, based on ship-to North America Three months ended December 31, (in thousands) 2019 2018 United States $ 9,827 $ 8,569 EMEA 5,941 2,435 APAC 1,241 420 North America 155 68 Total $ 17,164 $ 11,492
Summary of Revenue by Product	The table below sets forth revenues by products. Three months ended December 31, (in thousands) 2019 2018 Synthetic genes $ 7,836 $ 6,511 Oligo pools 1,242 810 DNA libraries 1,057 413 NGS tools 7,029 3,758 Total $ 17,164 $ 11,492
Summary of Revenue by Industry	The table below sets forth revenues by industry. Three months ended December 31, (in thousands) 2019 2018 Industrial chemicals $ 6,137 $ 5,346 Academic research 4,951 1,972 Healthcare 5,835 3,981 Agricultural 241 193 Total $ 17,164 $ 11,492

The company - Additional Inform

The company - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended
	May 31, 2019	Oct. 31, 2018	Dec. 31, 2019	Sep. 30, 2019
Accumulated deficit			$ (374,162)	$ (318,524)
IPO [Member]
Proceeds of underwritten public offering common stock	$ 84,300	$ 69,600
At The Market Offering [Member]
Proceeds of underwritten public offering common stock			$ 2,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Oct. 01, 2019
Operating lease right of use assets	$ 37,238
Operating lease liabilities	$ 35,910
Accounting Standards Update 2018-11 [Member]
Operating lease right of use assets		$ 35,800
Operating lease liabilities		34,300
Operating lease deferred rent		100
Operating lease prepaid rent		$ 1,600

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Assets
Assets, Totals	$ 103,107	$ 138,107
Cash [Member]
Assets
Assets, Totals	16,444	19,344
Money Market Funds [Member]
Assets
Assets, Totals	9,588	27,390
Corporate bonds [Member]
Assets
Assets, Totals	8,523	8,530
Commercial Paper [Member]
Assets
Assets, Totals	21,515	28,361
US Government Treasury Bills [Member]
Assets
Assets, Totals	47,037	54,482
Fair Value, Inputs, Level 1 [Member]
Assets
Assets, Totals	73,069	101,216
Fair Value, Inputs, Level 1 [Member] | Cash [Member]
Assets
Assets, Totals	16,444	19,344
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Assets
Assets, Totals	9,588	27,390
Fair Value, Inputs, Level 1 [Member] | US Government Treasury Bills [Member]
Assets
Assets, Totals	47,037	54,482
Fair Value, Inputs, Level 2 [Member]
Assets
Assets, Totals	30,038	36,891
Fair Value, Inputs, Level 2 [Member] | Corporate bonds [Member]
Assets
Assets, Totals	8,523	8,530
Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]
Assets
Assets, Totals	$ 21,515	$ 28,361

Balance sheet components - Sche

Balance sheet components - Schedule Of Accounts Notes Loans And Financing Receivable (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Trade Receivables	$ 12,475	$ 11,085
Other Receivables	920	1,313
Allowance for Doubtful Accounts	(341)	(294)
Accounts receivable, net	$ 13,054	$ 12,104

Inventory - Summary of Inventor

Inventory - Summary of Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Sep. 30, 2019
Inventory, Net [Abstract]
Raw Materials	$ 5,248	$ 4,900
Work-in-process	1,300	1,157
Finished Goods	868	1,273
Total inventories	$ 7,416	$ 7,330

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2019
Goodwill And Intangible Assets [Line Items]
Changes in carrying value of goodwill	$ 0		$ 0
Maximum [Member]
Goodwill And Intangible Assets [Line Items]
Total amortization expense related to intangible assets	$ 100,000	$ 100,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Summary of Intangible Assets Balances (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 1,240	$ 1,240
Accumulated amortization	(782)	(732)
Net book value	$ 458	$ 508
Developed Technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life in years	6 years	6 years
Gross carrying amount	$ 1,220	$ 1,220
Accumulated amortization	(762)	(712)
Net book value	$ 458	$ 508
Tradenames & Trademarks [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life in years	2 years	2 years
Gross carrying amount	$ 20	$ 20
Accumulated amortization	$ (20)	$ (20)

Commitments and contingencies -

Commitments and contingencies - Additional Information (Detail) - USD ($) $ in Millions	Feb. 06, 2020	Dec. 31, 2019
Loss Contingencies [Line Items]
Operating lease payment		$ 1.9
Operating lease expense		$ 2
Lease weighted-average remaining lease term		6 years 2 months 15 days
Lease Weighted Average Discount Rate		6.97%
Agilent [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Litigation settlement amount	$ 22.5

Commitments and contingencies_2

Commitments and contingencies - Schedule Of Future Minimum Rental Payments For Operating Leases (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2020	$ 6,757
2021	6,687
2022	6,762
2023	6,429
2024	6,388
Thereafter	11,291
Total minimum lease payments	44,314
Less: imputed interest	(8,404)
Total operating lease liabilities	35,910
Less: current portion	(8,371)
Operating lease obligations, net of current portion	$ 27,539

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Raw materials purchased from related party investor	$ 0.7	$ 1.2
Description of related party transactions	During the three months ended December 31, 2019 and 2018, the Company purchased raw materials from a related party investor in the amount of $0.7 million and $1.2 million, respectively. Payable balances and cash receipts and receivable balances with the related parties were immaterial as of December 31, 2019 and September 30, 2019.

Warrants - Summary of Issued Wa

Warrants - Summary of Issued Warrants for Its Redeemable Convertible Preferred Stock and Common Stock (Detail) - Common Stock [Member] - $ / shares	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019
Class of Warrant or Right [Line Items]
Number of shares underlying warrants	26,385	26,385
Warrants One [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants	18,854	18,854
Issuance date	Dec. 22, 2015	Dec. 22, 2015
Expiration date	Dec. 22, 2025	Dec. 22, 2025
Exercise price per share	$ 14.85	$ 14.85
Warrants Two [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants	7,531	7,531
Issuance date	Mar. 28, 2016	Mar. 28, 2016
Expiration date	Mar. 28, 2026	Mar. 28, 2026
Exercise price per share	$ 21.24	$ 21.24

Common stock - Additional info

Common stock - Additional information (Detail) - At The Market Offering [Member] $ / shares in Units, $ in Millions	3 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Sale of stock authorized amount	$ 50
Number of shares issued | shares	96,827
Price per share | $ / shares	$ 23.76
Proceeds of underwritten public offering common stock	$ 2

Stock-based compensation - Addi

Stock-based compensation - Additional Information (Detail) - USD ($) $ in Millions	Sep. 26, 2018	Dec. 31, 2019	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, stock options		$ 36.6
Unrecognized stock-based compensation expense, period for recognition		3 years 5 months 4 days
2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Minimum annual increase in share reserved for issuance	999,900
Annual automatic Increase in share reserved for issuance	4.00%
2018 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares may be issued	5,856,505
2018 ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Minimum annual increase in share reserved for issuance	249,470
Annual automatic Increase in share reserved for issuance	1.00%
Aggregate number of common stock shares reserved for issuance	275,225	305,551	56,081
2018 ESPP [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of payroll deduction to purchase common stock	15.00%
2015 ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP eligible employee common stock purchase price ratio	85.00%
Restricted Stock Units (RSUs) [Member] | 2018 ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, stock options		$ 15.1
Unrecognized stock-based compensation expense, period for recognition		3 years 9 months 10 days

Stock-based compensation - Acti

Stock-based compensation - Activity Under The Equity Incentive Plans (Detail) - 2018 Equity Incentive Plan [Member] $ / shares in Units, $ in Thousands	3 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available, Outstanding Beginning Balance	1,520,875
Shares available, Additional shares authorized	999,900
Shares available, Stock options granted	(935,273)
Shares available, Stock options forfeited	33,139
Shares available, Restricted stock units granted	(190,786)
Shares available, Shares withheld for payment of taxes	34,792
Shares available, Early exercised options repurchased	896
Shares available, Forfeiture of restricted stock units	3,483
Shares available, Outstanding Ending Balance	1,467,026
Number of options, Outstanding beginning balance	3,550,445
Options outstanding, Stock options granted	935,273
Options outstanding, Stock options exercised	(242,382)
Options outstanding, Stock options forfeited	(33,139)
Number of options, Outstanding ending balance	4,210,197
Weighted average exercise price per share, Outstanding Beginning Balance | $ / shares	$ 15.99
Weighted average exercise price per share, Stock options granted | $ / shares	24.08
Weighted average exercise price per share, Stock options exercised | $ / shares	6.95
Weighted average exercise price per share, Stock options forfeited | $ / shares	25.94
Weighted average exercise price per share, Outstanding Ending Balance | $ / shares	$ 18.23
Weighted average remaining contractual term, Outstanding	8 years 3 months
Aggregate intrinsic value, Outstanding | $	$ 31,997,934
Aggregate intrinsic value, Outstanding Vested or expected to vest and exercisable | $	$ 22,020,849
Options outstanding, Vested or expected to vest	4,210,197
Weighted average exercise price per share, Vested or expected to vest | $ / shares	$ 18.23
Weighted average remaining contractual term, Vested or expected to vest	8 years 6 months 3 days
Aggregate intrinsic value, Vested or expected to vest | $	$ 22,020,849
Options outstanding, Vested and exercisable	1,349,270
Weighted average exercise price per share, Vested and exercisable | $ / shares	$ 11.32
Weighted average remaining contractual term,Vested and exercisable	7 years 3 months 25 days
Aggregate intrinsic value, Vested and exercisable | $	$ 14,339,780

Stock-based compensation - Sche

Stock-based compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail) - Restricted Stock Units (RSUs) [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019
Nonvested Restricted Stock Units Activity [Line Items]
Number of shares, Outstanding Beginning Balance	462,370
Number of shares, granted	190,786
Number of shares, vested	(83,956)
Number of shares, forfeited	(3,483)
Number of shares, Outstanding Ending Balance	565,717	462,370
Expected to vest, Outstanding	565,717
Weighted average grant date fair value price per share, Outstanding Beginning Balance	$ 26.16
Weighted average grant date fair value price per share, granted	24.11
Weighted average grant date fair value price per share, vested	26.36
Weighted average grant date fair value price per share, forfeited	29.17
Weighted average grant date fair value price per share, Outstanding Ending Balance	25.42	$ 26.16
Weighted average grant date fair value price per share, Expected to vest	$ 25.42
Weighted average remaining contractual term, Outstanding	3 years 9 months 7 days	3 years 10 months 27 days
Weighted average remaining contractual term, Expected to vest	3 years 9 months 7 days
Aggregate intrinsic value	$ 14,383,146	$ 8,959,223
Aggregate intrinsic value, Expected to vest	$ 14,383,146

Stock-based compensation - Tota

Stock-based compensation - Total Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 3,697	$ 1,864
Cost of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	360	251
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	728	300
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 2,609	$ 1,313

Stock-based compensation - Summ

Stock-based compensation - Summary of Shares Reserved For Issuance (Detail)	Dec. 31, 2019shares
2018 Employee Stock Purchase Plan [Member]
Disclosure Of Employee Stock Purchase Plan [Line Items]
Additional shares authorized	249,470

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Computation of the Company's Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Numerator:
Net loss attributable to common stockholders	$ (55,638)	$ (22,639)
Denominator:
Weighted average shares used in computing net loss per share, basic and diluted	32,976,145	19,187,533
Net loss per share attributable to common stockholders, basic and diluted	$ (1.69)	$ (1.18)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Summary of Calculation of Diluted Net Loss Per Share (Detail) - shares	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	4,928,256	4,111,429
Options To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	4,210,197	3,500,040
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	13,635	81,473
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	565,717	395,698
Early Exercise Of Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	32,614	59,548
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	26,385	74,670
Employee Stock Purchase Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	79,708

Geographic, Product and Indus_3

Geographic, Product and Industry Information - Summary of Revenue by Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Revenue	$ 17,164	$ 11,492
United States [Member]
Segment Reporting Information [Line Items]
Revenue	9,827	8,569
EMEA [Member]
Segment Reporting Information [Line Items]
Revenue	5,941	2,435
Asia Pacific [Member]
Segment Reporting Information [Line Items]
Revenue	1,241	420
North America [Member]
Segment Reporting Information [Line Items]
Revenue	$ 155	$ 68

Geographic, Product and Indus_4

Geographic, Product and Industry Information - Summary of Revenue by Product (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Revenue	$ 17,164	$ 11,492
Synthetic Genes [Member]
Segment Reporting Information [Line Items]
Revenue	7,836	6,511
Oligo Pools [Member]
Segment Reporting Information [Line Items]
Revenue	1,242	810
DNA Libraries [Member]
Segment Reporting Information [Line Items]
Revenue	1,057	413
NGS Tools [Member]
Segment Reporting Information [Line Items]
Revenue	$ 7,029	$ 3,758

Geographic, Product and Indus_5

Geographic, Product and Industry Information - Summary of Revenue by Industry (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information [Line Items]
Revenue	$ 17,164	$ 11,492
Industrial Chemicals [Member]
Segment Reporting Information [Line Items]
Revenue	6,137	5,346
Academic Research [Member]
Segment Reporting Information [Line Items]
Revenue	4,951	1,972
Health Care [Member]
Segment Reporting Information [Line Items]
Revenue	5,835	3,981
Agricultural [Member]
Segment Reporting Information [Line Items]
Revenue	$ 241	$ 193

Subsequent events - Additional

Subsequent events - Additional Information (Detail) - At The Market Offering [Member] - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Jan. 31, 2020	Dec. 31, 2019
Subsequent Event [Line Items]
Number of shares issued		96,827
Proceeds of underwritten public offering common stock		$ 2
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares issued	2,142,853
Gross proceeds from issuance of stock	$ 47.7
Proceeds of underwritten public offering common stock	$ 46